Neuronetics Q4 Earnings: A Sell-the-News Setup or a Buy-the-Dip?

The immediate trading setup hinges on the mechanics of the Q4 results. The company delivered a clear beat, with preliminary revenue of $41.8 million topping the $40.66 million consensus. On the surface, that's a positive catalyst. Yet the growth story is skewed by a low prior-year quarter, creating a classic "sell-the-news" opportunity.

The key operational milestone is the achievement of positive operating cash flow of $0.9 million in the fourth quarter. That's a significant step for a growth-stage company, showing the business is starting to convert sales into real cash. However, the growth rate itself is the story here. The reported 23% year-over-year growth on an adjusted pro forma basis sounds robust, but it's a figure that benefits from a weak comparison. The prior-year quarter was likely depressed due to the integration of the Greenbrook acquisition and the closure of non-performing clinics. This means a large portion of the growth is a base effect, not necessarily a new, accelerated trend.

The bottom line is that the beat was real, and the cash flow achievement is meaningful. But for a stock trading on momentum, the market may view this as a "good news is bad news" scenario. The strong numbers were largely expected given the 86% as-reported growth, and the adjusted pro forma rate, while positive, doesn't represent a step-change. With the full results still weeks away, the initial reaction is likely to be a relief rally that quickly fades as the "what's next" question takes over. The setup favors a short-term profit-taking move after the initial pop.

The Greenbrook Engine: Synergies vs. Integration Risk

The core driver of Neuronetics' growth is now the Greenbrook TMS clinic acquisition, which became effective on December 9, 2024. This transaction is the primary engine behind the revenue surge, with the company expecting to realize over $22 million in annualized cost synergies from the integration. Management has already signaled progress, achieving cash flow breakeven in the third quarter of 2025 as a key milestone.

The tension here is between promised benefits and execution risk. The synergy target is substantial, but realizing it requires seamless integration of operations, sales forces, and clinic management. Evidence shows the clinic business is scaling, with Greenbrook clinic revenue growing 25% on an adjusted pro forma basis in Q3 2025. Yet, the path to breakeven and beyond depends on executing the planned cost cuts without disrupting patient care or clinic performance.

For the stock, this creates a binary setup. If integration proceeds smoothly, the synergies will flow through to margins and cash flow, validating the acquisition thesis. Any stumble, however, would directly pressure the financial targets and could delay the path to sustained profitability. The recent achievement of positive operating cash flow in Q4 2025 is a positive signal, but it's still early days. The market will be watching for the next quarter's results to see if the promised $22 million in annual savings begins to materialize.

Valuation and the Path to a Sustainable Run Rate

The Q4 beat is a positive data point, but it doesn't change the fundamental valuation question. The stock trades at a premium to Neuronetics' standalone 2024 revenue of $74.5 million, a multiple that prices in the transformative Greenbrook story. The full-year 2025 numbers highlight the disconnect. Revenue hit $149.2 million, a staggering 99% on an as-reported basis. Yet the adjusted pro forma growth, which strips out the acquisition's noise, was just 15%. That's the real growth story for the core business.

The key watchpoint is whether the standalone TMS system sales can accelerate beyond that 15% adjusted pro forma rate. The latest quarter showed NeuroStar revenue up 9% on a pro-forma basis. This is the engine that must drive future multiples. If it stalls, the valuation premium is built on a shaky foundation, as the entire growth narrative becomes reliant on the clinic business's performance and synergy realization.

The bottom line is that the valuation depends entirely on the standalone business's ability to grow. The Greenbrook acquisition provides scale and a path to cash flow breakeven, but it does not inherently create a higher-growth trajectory for the core medical device sales. For the stock to sustain its premium, investors need to see the NeuroStar segment start to pick up speed. Until then, the event-driven setup remains one of waiting for the next catalyst to prove the thesis.

Catalysts and Risks: What to Watch After the Call

The March 17 conference call is the first detailed look at the financial impact of the Greenbrook integration and the updated 2026 guidance. This event will determine whether the initial relief rally holds or fades. The market needs to see concrete numbers on the promised $22 million in annualized cost synergies and how much of the Q4 revenue beat was driven by clinic operations versus core system sales. Management's commentary on the standalone NeuroStar business's trajectory will be critical. If the adjusted pro forma growth rate for the core system sales reverts to the pre-acquisition level of around 9-11%, the entire growth premium in the stock valuation is at risk.

The major risk is that the high reported growth rate is not sustainable. The 23% adjusted pro forma growth in Q4 is a significant step up from the 11% rate in Q3, but it still falls far short of the 86% as-reported surge driven by the acquisition. The bullish thesis hinges on this adjusted growth accelerating further. If the call shows the standalone business stalling, the stock could face a sharp de-rating as investors reassess the valuation multiple.

Another factor to watch is management's commentary on the CEO transition. President Keith Sullivan has announced his retirement effective June 30, 2026. While the company has a succession plan, any uncertainty or lack of clarity around the transition could introduce volatility. The call provides the first opportunity for investors to gauge the stability of the leadership team as it navigates the integration and sets new targets.

The bottom line is that the post-earnings setup is binary. The March 17 call must deliver a clear path to accelerating standalone growth and tangible progress on synergies to justify the premium. Any stumble on these fronts, or a lack of confidence in the leadership transition, could quickly invalidate the bullish thesis and trigger a sell-off.